🚀 VC round data is live in beta, check it out!
Biomm Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biomm and similar public comparables like Cereno Scientific, ProQR Therapeutics, Medeze Group, Compugen and more.
Biomm Overview
About Biomm
Biomm SA is engaged in biotechnological processes for the production of active pharmaceutical ingredients and other industrial purposes, such as enzymes used in the production of Biofuels.The Company is patented for insulin production.The company develops processes for the production of insulin and other biotech products, as well as processes for other industrial applications, such as enzymes that are used in the production of biofuels.
Founded
2002
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$218M
Biomm Financials
Biomm reported last fiscal year revenue of $53M and EBITDA of $2M.
In the same fiscal year, Biomm generated $17M in gross profit, $2M in EBITDA, and had net loss of ($1M).
Biomm P&L
In the most recent fiscal year, Biomm reported revenue of $53M and EBITDA of $2M.
Biomm expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $53M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $17M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 32% | XXX | XXX | XXX |
| EBITDA | — | XXX | $2M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 5% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (2%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (2%) | XXX | XXX | XXX |
| Net Debt | — | — | $15M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Biomm Stock Performance
Biomm has current market cap of $208M, and enterprise value of $218M.
Market Cap Evolution
Biomm's stock price is $1.52.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $218M | $208M | 24.0% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiomm Valuation Multiples
Biomm trades at 4.1x EV/Revenue multiple, and 88.5x EV/EBITDA.
Biomm Financial Valuation Multiples
As of April 10, 2026, Biomm has market cap of $208M and EV of $218M.
Equity research analysts estimate Biomm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biomm has a P/E ratio of (158.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $208M | XXX | $208M | XXX | XXX | XXX |
| EV (current) | $218M | XXX | $218M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 88.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (232.0x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 13.1x | XXX | XXX | XXX |
| P/E | — | XXX | (158.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biomm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Biomm Margins & Growth Rates
Biomm's revenue in the last fiscal year grew by 88%.
Biomm Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 88% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (124%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Biomm Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cereno Scientific | XXX | XXX | XXX | XXX | XXX | XXX |
| ProQR Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Medeze Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Compugen | XXX | XXX | XXX | XXX | XXX | XXX |
| Atrium Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biomm M&A Activity
Biomm acquired XXX companies to date.
Last acquisition by Biomm was on XXXXXXXX, XXXXX. Biomm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Biomm
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBiomm Investment Activity
Biomm invested in XXX companies to date.
Biomm made its latest investment on XXXXXXXX, XXXXX. Biomm invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Biomm
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biomm
| When was Biomm founded? | Biomm was founded in 2002. |
| Where is Biomm headquartered? | Biomm is headquartered in Brazil. |
| Is Biomm publicly listed? | Yes, Biomm is a public company listed on B3. |
| What is the stock symbol of Biomm? | Biomm trades under BIOM3 ticker. |
| When did Biomm go public? | Biomm went public in 2000. |
| Who are competitors of Biomm? | Biomm main competitors are Cereno Scientific, ProQR Therapeutics, Medeze Group, Compugen. |
| What is the current market cap of Biomm? | Biomm's current market cap is $208M. |
| What is the current revenue of Biomm? | Biomm's last fiscal year revenue is $53M. |
| What is the current EV/Revenue multiple of Biomm? | Current revenue multiple of Biomm is 4.1x. |
| Is Biomm profitable? | No, Biomm is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.